Twenty-one strains of Campylobacter pylori (Campylobacter pyloridis) were tested for susceptibility to norfloxacin and other agents by the serial agar dilution method. Ampicillin (MIC for 90% of isolates [MIC901, 0.016 ,ug/ml) and famotidine (MIC90, >1,024 ,ug/ml) were, respectively, the most and the least active of the agents tested. Norfloxacin (MICg, 1 p,g/ml) and imipenem (MIC90, 0.125 p,g/ml) were substantially active against this organism.
Interest in Campylobacter pylori (Campylobacter pyloridis) as a possible cause of gastritis and peptic ulcer disease has increased significantly since this organism was first described in 1982 by Marshall and Warren (1, 7, 8) . Among the various properties of C. pylori that have been investigated, susceptibility to antibacterial and antiulcer drugs has been the focus of attention (3, 5, 9) . In general, C. pylori has been found to be highly susceptible to most antibiotics except nalidixic acid, vancomycin, trimethoprim, and sulfonamides. The antiulcer drugs cimetidine and ranitidine have been shown to have no antibacterial activity against this organism (3).
Norfloxacin is a new 4-quinolone congener of nalidixic acid with a greatly enhanced antibacterial spectrum compared with that of the parent compound. This drug is now being used worldwide as a highly effective agent in the treatment of urinary and gastrointestinal tract pathogens (4) . In this report, we present previously unreported data on the in vitro antibacterial activity of norfloxacin, imipenem, and famotidine against C. pylori.
Of the 21 C. pylori isolates in this study, 20 were obtained from Lima, Peru, through the initiative of R.H.G. The remaining strain was a gift from B. J. Marshall, Royal Perth Hospital, Perth, Western Australia, Australia. These test strains represented single isolates recovered from gastric mucosal biopsies. The identity of each strain was confirmed by gram stain and by urease, oxidase, catalase, and alkaline phosphatase tests (6) (7) (8) 10 distilled water. Inocula were prepared in brain heart infusion broth from 4-day-old cultures grown in brain heart infusion agar supplemented with 7% lysed horse blood and adjusted to McFarland standard 1, equivalent to approximately 5 x 108 CFU/ml. Test plates contained brain heart infusion agar enriched with 7% lysed horse blood and serial twofold dilutions of each of the drugs tested. Plates were inoculated with a multipoint device (Denley Instruments, Bolney, England) capable of delivering 1-pAl samples and incubated for 4 days at 37°C in an atmosphere of 10% CO2, 5% 02, and 85% N2. MIC was defined as the lowest concentration of the test compound preventing colony formation.
MICs for 50 and 90% (MIC50 and MIC90, respectively) of 21 C. pylori strains treated with each of seven antibacterial agents and two H2 receptor antagonists are shown in Table 1 .
These bacterial isolates were very susceptible (MIC90, '1 ,ug/ml) to norfloxacin, imipenem, ampicillin, erythromycin, gentamicin, and tetracycline and were resistant (MIC90, -128 ,ug/ml) to nalidixic acid, cimetidine, and famotidine.
Ampicillin (MIC90, 0.016 ,ug/ml) and famotidine (MIC90, >1,024 ,ug/ml) were, respectively, the most and the least active of the compounds tested. Our susceptibility results for erythromycin, gentamicin, nalidixic acid (9) , and cimetidine are in close agreement with results reported elsewhere (3, 9) . Clinical studies are needed to determine whether antibacterial therapy with norfloxacin or other highly active agents 
